Buy Tesamorelin Peptide 10 mg | GHRH Analog ≥99% Purity | SourceTides

Buy Tesamorelin Peptide 10 mg from SourceTides and receive the most clinically evidenced GHRH analog available for laboratory research — supplied at ≥99% purity, confirmed by reverse-phase HPLC and mass spectrometry on every production batch. Tesamorelin is a synthetic 44-amino-acid analog of endogenous growth hormone-releasing hormone (GHRH), modified at the N-terminus with a trans-3-hexenoyl group that confers superior resistance to enzymatic degradation compared with native GHRH. It is the only GHRH-class peptide to hold FDA approval — granted in 2010 under the brand name Egrifta for the reduction of excess visceral adipose tissue (VAT) in HIV-infected patients with lipodystrophy — and the only peptide in its class backed by Phase III randomised, double-blind, placebo-controlled clinical trial data with body composition imaging endpoints.

Researchers looking to buy Tesamorelin Peptide online for preclinical or translational studies gain access to one of the most thoroughly characterised peptides in the GHRH receptor class, with a peer-reviewed evidence base spanning visceral fat reduction, non-alcoholic fatty liver disease (NAFLD), cognitive function in aging populations, and IGF-1 axis regulation. Every SourceTides Tesamorelin 10 mg vial ships with a batch-specific Certificate of Analysis (CoA) and cold-chain packaging. This product is supplied exclusively for in-vitro and laboratory research purposes only and is not approved for general human use beyond its specific FDA-approved indication.

Buy Tesamorelin Peptide 10 mg — Full Technical Specifications

Before designing any Tesamorelin research protocol, researchers need precise physicochemical and handling data. The table below consolidates all key parameters for the SourceTides Tesamorelin 10 mg vial.

Buy Tesamorelin Peptide Online — What Is It and Why Does the Research Matter?

Tesamorelin is a structural analog of endogenous GHRH — the hypothalamic peptide that governs the physiological pulsatile release of growth hormone from the anterior pituitary. Native GHRH has a critically short plasma half-life, degraded within minutes by the ubiquitous enzyme dipeptidyl peptidase IV (DPP-4), which cleaves the Tyr¹-Ala² N-terminal bond. This rapid clearance renders native GHRH impractical as a research tool for sustained GH-axis stimulation studies.

Tesamorelin solves this problem through N-terminal chemical modification: a trans-3-hexenoyl group is attached to the tyrosine residue at position 1, physically blocking DPP-4 access and extending plasma stability from seconds to 26–38 minutes in human pharmacokinetic studies. This is not a truncated or active-fragment peptide like TB-500 or Ipamorelin — Tesamorelin contains the complete 44-amino acid GHRH sequence, ensuring all secondary signalling pathways of the native molecule are engaged alongside the primary GHRHR-cAMP-GH secretion cascade. This completeness is why researchers describe Tesamorelin as the most “physiologically accurate” GHRH analog available for research. (NIH LiverTox — Tesamorelin drug and pharmacology profile)

When researchers want to order Tesamorelin peptide for a GH-axis study, the critical differentiator versus other GH secretagogues is the preserved negative feedback loop. Tesamorelin stimulates GH release through the natural hypothalamic–pituitary–GH (HPGH) axis, meaning somatostatin and IGF-1 feedback continue to regulate GH pulsatility. This is mechanistically distinct from synthetic GH administration, which bypasses this feedback entirely, and from ghrelin-receptor agonists (GHRPs such as Ipamorelin), which act on an entirely separate receptor pathway. This physiological preservation makes Tesamorelin an important research probe for studying endocrine regulation under controlled conditions.

Tesamorelin Peptide Mechanism of Action — GHRH Receptor to IGF-1 to Fat Metabolism

Understanding how Tesamorelin works at the receptor and downstream signalling level is essential for designing valid research protocols. The cascade operates across four linked biological layers.

GHRH Receptor Binding and cAMP Signalling

Tesamorelin binds with high affinity to the GHRH receptor (GHRHR) expressed on anterior pituitary somatotroph cells. Receptor engagement activates adenylate cyclase, elevating intracellular cyclic AMP (cAMP) by 20–25% in pituitary cell culture systems. Elevated cAMP activates protein kinase A (PKA), which phosphorylates downstream transcription factors controlling GH gene expression and exocytosis of stored GH from secretory granules. Research models document a 2–5× increase in GH secretion in rat pituitary cultures at 1–10 nM concentrations, and 3–4× amplification of pulsatile GH pulses in rodent in-vivo models. (Protide Health — Tesamorelin GHRHR signalling data)

Pulsatile GH Release and Preserved Feedback Architecture

Unlike exogenous recombinant human growth hormone (rhGH), which produces a sustained, non-physiological GH elevation that suppresses endogenous GH secretion via negative feedback, Tesamorelin stimulates pulsatile GH release that mirrors endogenous secretory patterns. Somatostatin (SRIF) from the hypothalamus continues to provide GH release inhibition, and rising IGF-1 feeds back at both the pituitary and hypothalamic levels to modulate GH pulse amplitude and frequency. Phase III clinical trial data confirmed that Tesamorelin produced mean IGF-1 increases of approximately 108 ng/mL versus minimal change with placebo, within the physiological range, without suppressing the hypothalamic-pituitary axis. This feedback preservation is a key research advantage over direct GH administration in studies examining the GH axis under naturalistic conditions. (ScienceDirect — Tesamorelin pharmacology overview)

IGF-1 Mediated Downstream Effects — Lipolysis, Anabolism and Metabolic Regulation

GH released by Tesamorelin stimulation acts on multiple peripheral tissues. In the liver, GH stimulates IGF-1 synthesis, which in turn mediates downstream anabolic and metabolic effects across target tissues. In adipose tissue, elevated GH directly activates hormone-sensitive lipase (HSL), increasing free fatty acid mobilisation from stored triglycerides — a process that in clinical research models occurs preferentially in visceral adipose tissue (VAT) (deep abdominal fat surrounding the organs) rather than subcutaneous fat. This VAT selectivity is one of Tesamorelin’s most studied and clinically documented properties, forming the basis of its FDA approval. In skeletal muscle, upregulation of myogenic markers (MyoD, myogenin) by 15–18% has been recorded in cell culture models, consistent with IGF-1’s established anabolic effects on muscle protein synthesis.

Hepatic Lipid Metabolism — NAFLD Research Pathway

Beyond adipose tissue, elevated GH and IGF-1 signalling suppresses de novo lipogenesis (DNL) in the liver — the hepatic synthesis of new fat from carbohydrate substrates — while increasing hepatic fatty acid beta-oxidation. These dual effects (reduced fat synthesis + increased fat burning) provide the mechanistic rationale for Tesamorelin’s documented effects on liver fat content in NAFLD research models, detailed below. A transcriptomic analysis of paired liver biopsy specimens from a randomised controlled trial identified differential modulation of hepatic inflammatory gene pathways and increased oxidative phosphorylation pathway expression in Tesamorelin-treated subjects versus placebo. (JCI Insight — Tesamorelin hepatic transcriptomics NAFLD 2020)

Tesamorelin Research Areas — Clinical and Preclinical Evidence Summary

Tesamorelin is unique among research peptides in that several of its research domains are supported by Phase III randomised controlled trial data, not merely animal models. The following table maps the evidence tier for each major research area.

Phase III data referenced is from FDA-approved indication (HIV-associated lipodystrophy). NAFLD, cognitive, and body composition data are from exploratory and Phase II trials. All data is provided for research context only. SourceTides supplies Tesamorelin exclusively for in-vitro laboratory research use.

Tesamorelin Peptide for Visceral Fat Research — The Phase III Evidence Base

The most extensively documented research application for Tesamorelin is visceral adipose tissue reduction. The pivotal Phase III evidence comes from two landmark trials — LIPO-010 and CTR-1011 — and their pooled analysis by Falutz and colleagues. The 2007 Phase III trial published in The New England Journal of Medicine (Falutz et al., PMID: 17636085) demonstrated statistically significant reductions in VAT measured by CT imaging, with approximately 15% reduction in VAT relative to placebo over 26-week treatment periods. The pooled analysis of 806 patients across these trials confirmed the consistency of this effect across patient subgroups, and documented concurrent improvements in trunk-to-limb fat ratios and triglyceride profiles.

What makes the Tesamorelin VAT research particularly valuable for study design is the selectivity for visceral over subcutaneous fat. CT imaging data showed that Tesamorelin preferentially targets the metabolically active VAT depot (the intra-abdominal fat that surrounds the liver, intestines, and other visceral organs and is most associated with cardiometabolic risk) rather than the relatively inert subcutaneous fat layer. This selectivity appears mechanistically linked to the higher density of GH receptors in visceral adipocytes compared with subcutaneous fat cells, making visceral fat more responsive to GH-mediated hormone-sensitive lipase activation. (FDA Prescribing Information — Egrifta WR, 2025)

Tesamorelin for NAFLD Research — Liver Fat and Fibrosis Data

Beyond its approved visceral fat indication, one of the most scientifically significant emerging Tesamorelin research domains is non-alcoholic fatty liver disease (NAFLD). A randomised, double-blind, multicentre trial (Stanley, Fourman, Grinspoon et al., published in The Lancet HIV 2019, PMID: 31611038) enrolled 61 people with HIV infection and hepatic fat fraction ≥5% by proton magnetic resonance spectroscopy. Participants were randomly assigned 1:1 to Tesamorelin 2 mg daily versus identical placebo for 12 months. Tesamorelin treatment significantly reduced liver fat content and, critically, prevented fibrosis progression — a distinction that makes it the first pharmacological strategy demonstrated to be effective against NAFLD in people with HIV. (PMC — Stanley et al. NAFLD Lancet HIV 2019)

A follow-up transcriptomic analysis of paired liver biopsy specimens (Fourman, Billingsley, Grinspoon et al., published in JCI Insight 2020, PMID: 32701508) identified specific hepatic gene pathways differentially modulated by Tesamorelin — finding significantly decreased hepatic inflammatory gene expression and increased oxidative phosphorylation pathway activity in treated subjects. This gene-level data provides mechanistic depth to the clinical liver fat outcomes and opens research questions about Tesamorelin’s potential utility in the broader general NAFLD population (a Phase II trial, NCT03375788, has investigated this). (PubMed — Fourman et al. JCI Insight 2020)

Tesamorelin Peptide and Cognitive Function Research — The GH–Brain Connection

One of the less-expected but increasingly researched Tesamorelin applications is cognitive function in aging populations. A randomised controlled trial evaluating GHRH stimulation in older adults with mild cognitive impairment (Baker et al., published in Archives of Neurology 2012, PMID: 22926095) found that the Tesamorelin-treated group demonstrated improvements in executive function and verbal memory compared with placebo.

The proposed biological mechanism involves GH/IGF-1 signalling in hippocampal neurons and prefrontal cortical circuits. GH receptors and IGF-1 receptors are expressed throughout the brain, with particularly high density in the hippocampus — the structure critical for memory formation and retrieval. Age-related decline in GH secretory amplitude (somatopause) has been associated with reduced hippocampal volume and impaired synaptic plasticity in animal models. By restoring a more youthful GH/IGF-1 pulsatile environment, Tesamorelin may support neuronal maintenance and synaptic function in aging brains — a hypothesis of significant interest in the Alzheimer’s prevention research field, where early intervention in the GH axis is an active area of investigation. (ClinicalPub — Tesamorelin cognitive and NAFLD research overview)

What Types of Research Is Tesamorelin Peptide 10 mg Most Relevant For?

Researchers across several disciplines regularly source Tesamorelin peptide for preclinical and translational models. Understanding the research context helps confirm protocol fit before ordering.

Tesamorelin Pharmacokinetics — Stability, Half-Life and Dosing Implications for Research

Tesamorelin’s N-terminal hexenoyl modification directly determines its pharmacokinetic profile and distinguishes it from native GHRH in practically every relevant parameter.

Tesamorelin Peptide Side Effects and Adverse Events — What Research and Clinical Data Shows

For researchers designing Tesamorelin preclinical or translational study protocols, understanding the known adverse event profile from clinical data is important for safety endpoint selection and interpreting results. The following information is drawn from published clinical trial data and the FDA prescribing information for Egrifta — not from SourceTides product claims.

Adverse event data sourced from FDA Egrifta prescribing information and NIH LiverTox database. This data describes clinical findings from the FDA-approved human indication only. SourceTides supplies Tesamorelin for in-vitro laboratory research use only — not for human administration.

High-Purity Tesamorelin Peptide for Sale — SourceTides Quality Control

Tesamorelin is a 44-amino-acid peptide — considerably larger and more structurally complex than shorter research peptides. Synthesis of a full 44-residue sequence requires stringent SPPS (solid-phase peptide synthesis) protocols and rigorous purification to remove deletion sequences, truncation variants, and racemisation by-products that are more prevalent in longer peptide chains. The hexenoyl N-terminal modification adds an additional verification requirement — confirming correct N-terminal acylation by mass spectrometry is essential, as an unmodified or incorrectly acylated N-terminus would lack DPP-4 resistance.

Tesamorelin Peptide Regulatory and Legal Status — 2025 Overview

View SourceTides’ full shipping and compliance policy.

Buy Tesamorelin Peptide vs. Other GHRH Analogs and GH Secretagogues — Research Comparison

Tesamorelin Peptide Peer-Reviewed Research References

Frequently Researched Alongside Tesamorelin — SourceTides GH-Axis Peptide Catalogue

Researchers studying the GHRH–GH–IGF-1 axis or body composition biology often need complementary peptides for comparison or combination protocols. The SourceTides catalogue covers the full GH secretagogue class:

• Sermorelin (GHRH 1-29) — Shorter GHRH analog; commonly used in comparative GHRHR activation studies
• CJC-1295 — Long-acting GHRH analog with DAC modification; extended GH pulse duration research
• Ipamorelin — Selective GHSR agonist; dual-receptor GH axis research when combined with GHRH analogs
• MOTS-c — Mitochondria-derived exercise mimetic; metabolic research complement to Tesamorelin’s visceral fat work
• BPC-157 — GI mucosal protection and musculoskeletal repair research peptide
• Browse All Research Peptides — Full SourceTides catalogue

Frequently Asked Questions — Buy Tesamorelin Peptide 10 mg

buy tesamorelin peptide, tesamorelin 10mg, tesamorelin for sale, buy tesamorelin peptide 10 mg, tesamorelin peptide online, tesamorelin GHRH analog, tesamorelin research peptide, order tesamorelin peptide, tesamorelin USA, tesamorelin CoA, tesamorelin high purity, tesamorelin lyophilised, buy GHRH analog online, tesamorelin UK